These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 9541166)

  • 1. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
    Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
    J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
    Siegel EG; Scharf G; Gallwitz B; Mentlein R; Morys-Wortmann C; Fölsch UR; Schmidt WE
    Eur J Clin Invest; 1999 Jul; 29(7):610-4. PubMed ID: 10411667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered beta-cells secreting dipeptidyl peptidase IV-resistant glucagon-like peptide-1 show enhanced glucose-responsiveness.
    Islam MS; Rahman SA; Mirzaei Z; Islam KB
    Life Sci; 2005 Jan; 76(11):1239-48. PubMed ID: 15642594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
    Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF; Plamboeck A; Møller S; Holst JJ
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.
    Burcelin R; Dolci W; Thorens B
    Metabolism; 1999 Feb; 48(2):252-8. PubMed ID: 10024091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
    O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
    Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.
    Deacon CF; Hughes TE; Holst JJ
    Diabetes; 1998 May; 47(5):764-9. PubMed ID: 9588448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro.
    Gallwitz B; Ropeter T; Morys-Wortmann C; Mentlein R; Siegel EG; Schmidt WE
    Regul Pept; 2000 Jan; 86(1-3):103-11. PubMed ID: 10672909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
    Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
    Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A synthetic glucagon-like peptide-1 analog with improved plasma stability.
    Ritzel U; Leonhardt U; Ottleben M; Rühmann A; Eckart K; Spiess J; Ramadori G
    J Endocrinol; 1998 Oct; 159(1):93-102. PubMed ID: 9795346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo.
    Hinke SA; Manhart S; Kühn-Wache K; Nian C; Demuth HU; Pederson RA; McIntosh CH
    J Biol Chem; 2004 Feb; 279(6):3998-4006. PubMed ID: 14610075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
    Mentlein R; Gallwitz B; Schmidt WE
    Eur J Biochem; 1993 Jun; 214(3):829-35. PubMed ID: 8100523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.
    Hansen L; Deacon CF; Orskov C; Holst JJ
    Endocrinology; 1999 Nov; 140(11):5356-63. PubMed ID: 10537167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.